Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Spark Therapeutics, Inc. Is Getting Hammered Today

By Cory Renauer – Updated Dec 12, 2017 at 10:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The latest data from Spark's hemophilia program bodes well for a potential competitor.

What happened

Shares of Spark Therapeutics, Inc. (ONCE), a biotech developing gene therapies, fell hard this morning after the company reported hemophilia trial data that bodes well for rival BioMarin Pharmaceutical Inc. (BMRN 2.47%). Spark Therapeutics stock has fallen about 40% as of 11:01 a.m. EST on Monday. 

So what 

Spark's stock surged when SPK-8011 produced some encouraging data earlier this year. It's giving a lot of its gains back today after the company released data that suggests a potential competitor from BioMarin might have the upper hand from this point forward.

Chalk drawing of an upward sloping chart that abruptly reversed course.

Image source: Getty Images.

SPK-8011 is a one-time gene therapy that aims to help hemophiliacs produce necessary clotting factors. Although Spark's candidate helped knock back dangerous uncontrolled bleeds to essentially zero, investors are troubled by a spotty clotting factor production benefit.

In short, one patient receiving a high dose of Spark's SPK-8011 produced clotting factors as high as 12% of normal while a patient receiving a low dose produced clotting factors as high as 24% of normal.

Now what

BioMarin's candidate hasn't been measured in a head-to-head trial against Spark's so we need to take any comparisons with a big grain of salt. That said, the differences look pretty big. BioMarin's valoctocogene roxaparvovec (formerly BMN 270) helped three patients with a 48-week observation produce clotting factors at an average of 49% of normal.

While the future of Spark's fledgling hemophilia program seems even less certain now than it did a few days ago, the company could launch its first commercial-stage drug in the new year. The U.S. Food and Drug Administration is expected to announce an approval decision for the company's Luxturna as the first treatment for a rare cause of blindness in the weeks ahead. 

Editor's note: A previous version of this article incorrectly listed Pfizer as a partner on SPK-8011.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends BioMarin Pharmaceutical. The Motley Fool has a disclosure policy.

Stocks Mentioned

Spark Therapeutics Stock Quote
Spark Therapeutics
Pfizer Stock Quote
$50.91 (-0.33%) $0.17
BioMarin Pharmaceutical Stock Quote
BioMarin Pharmaceutical
$105.56 (2.47%) $2.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.